Duloxetine is a selective serotonin and noradrenaline reuptake inhibitor used as antidepressant. However, its mechanisms of action are not fully understood. This study investigated the effect of duloxetine in the mouse forced swimming test (FST) Moreover, the administration of duloxetine (10 mg/kg) produced a reduction in NOx levels in the hippocampus and cerebral cortex. Altogether the results suggest that the effect of duloxetine in the FST is dependent on either a blockade of NMDA receptors or an inhibition of NO. In addition, our results further reinforce the role of NMDA receptors and L-arginine-NO-cGMP pathway, besides the monoaminergic systems, in the mechanism of action of current prescribed antidepressant agents.
Introduction
Depression is a disorder that has a high lifetime prevalence (around 16%) and is often manifested with symptoms at the psychological, behavioral and physiological levels. Suicide is usually a consequence of depression and other deleterious health-related effects have been reported (Wong and Licinio, 2001) . Despite the devastating impact of depression, its etiology or pathophysiology is not well established. The monoaminergic systems (serotonergic, noradrenergic and dopaminergic) have received a great attention in neurobiological studies of depression (Wong and Licinio, 2001) . Some clinical reports suggest that the combination of selective serotonin (5-HT) reuptake inhibitors with selective noradrenaline (NE) reuptake inhibitors may present a therapeutic advantage, resulting in a more effective or rapid antidepressant effect in comparison to each drug given alone (Shelton et al., 2005; Thase et al., 2007) .
Duloxetine is a drug that inhibits 5-HT and NE reuptake, with weak effects on dopamine reuptake (Hunziker et al., 2005) . It is used in the treatment of depression (Detke et al., 2004) , anxiety (Carter and McCormack, 2009 ) and pain (Bellingham and Peng, 2010) . It has been proposed that 5-HT and NE reuptake inhibitors may result in higher remission rates of major depressive disorder than therapy with selective inhibitors of 5-HT reuptake (Shelton et al., 2005; Thase et al., 2001; Smith et al., 2002) . It has been reported that duloxetine has some advantages over other antidepressants, since it has greater effectiveness than fluoxetine and paroxetine in patients with moderate to severe depression (Thase et al., 2007) and has a better tolerability than venlafaxine (Stahl et al., 2005) . Moreover, it is generally well tolerated and has fewer adverse effects such as dry mouth, nausea, fatigue (Hunziker et al., 2005) , sexual dysfunction (Stahl et al., 2005) and little or no effect on the cardiovascular system (Stahl et al., 2005; Hunziker et al., 2005) . Of note, duloxetine-treated patients demonstrated clinically meaningful improvements within the first weeks of treatment (Brannan et al., 2005) . Regarding preclinical studies, it was shown that duloxetine reduced the immobility time in the forced swimming test (FST) in rats (Ciulla et al., 2007; Rénéric and Lucki, 1998) .
Several clinical studies have demonstrated abnormalities in glutamate function in mood disorders. Some studies have indicated that compounds that reduce transmission at N-methyl-D-aspartate (NMDA) receptors and NMDA receptor antagonists exhibit antidepressant-like effects (Sanacora et al., 2008; Skolnick, 1999; Zarate et al., 2006) . Depressed patients also showed a significant improvement after the acute administration of ketamine, a non-competitive NMDA receptor antagonist (Berman et al., 2000; Zarate et al., 2006) . Moreover, it is also noteworthy that NMDA receptor antagonists exert synergistic antidepressant-like effects with classical antidepressants in the FST (Rogóz et al., 2002) . Also, the use of MK801, a non-competitive NMDA antagonist, during imipramine withdrawal following chronic imipramine treatment resulted in significant suppression of swim stress immobility (Harvey et al., 2002) .
The NMDA receptor stimulation induces the activation of nitric oxide (NO) synthase (NOS). The activated NOS then converts L-arginine to NO and L-citrulline (Esplugues, 2002) . NO is a signaling molecule in the brain and has been implicated in depression (Da Silva et al., 2000; Harkin et al., 1999 Harkin et al., , 2004 Heiberg et al., 2002) . It has been demonstrated that the reduction of NO levels within the hippocampus can induce antidepressant-like effects, thus implicating endogenous hippocampal NO in the neurobiology of depression (Joca and Guimarães, 2006) . In addition, plasma nitrate concentrations were significantly increased in depressed patients, suggesting that NO production is enhanced in depression (Suzuki et al., 2001) . Several studies have demonstrated that NOS inhibitors, depending on their concentration, exert antidepressant-like effects (Da Silva et al., 2000; Harkin et al., 2003 Harkin et al., , 2004 Volke et al., 2003) . Some of the physiological actions of NO are mediated through the enzyme guanylate cyclase (sGC) with the consequent increase in cyclic guanosine monophosphate (cGMP) levels. It is currently accepted that the NO-cGMP pathway is the main effector of NO actions in the brain (Esplugues, 2002) .
Although the behavioral studies using duloxetine in the FST support its antidepressant properties (Ciulla et al., 2007; Rénéric and Lucki, 1998) , its mechanisms of action besides the monoaminergic system are not fully understood. The present study examined whether duloxetine produces antidepressant-like effect in the FST and also in another model predictive of antidepressant activity, the TST, in mice. These behavioral tests have good predictive value for antidepressant potency in man (Cryan et al., 2002) . Considering that the blockade of NMDA receptor is associated with reduced levels of NO and cGMP (Snyder, 1992) and the inhibition of both NOS and sGC may, depending on the dose, elicit antidepressant-like effects in the FST (Eroglu and Caglayan, 1997; Da Silva et al., 2000; Harkin et al., 2003; Heiberg et al., 2002; Volke et al., 2003; Yildiz et al., 2000) , we investigated whether NMDA receptors and L-arginine-NO-cGMP pathway may be involved in the effect of acute duloxetine administration in mouse FST.
Materials and methods

Animals
Swiss albino female mice (30-40 g, 55-70 days old) were maintained at 21-23°C with free access to water and food, under a 12:12 h light/dark cycle (lights on at 7:00 h). Animals were obtained from the Central Biothery of Universidade Federal de Santa Catarina (UFSC). All manipulations were carried out between 9:00 a.m. and 4:00 p.m., with each animal used only once. All procedures in this study were performed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals . The experiments were performed after approval of the protocol by the Institutional Ethics Committee and all efforts were made to minimize animals' suffering and to reduce the number of animals used in the experiments.
Drugs and pharmacological treatments
Duloxetine HCl (Eli Lilly & Co.), L-arginine, methylene blue, N-methyl-D-aspartate (NMDA), 1H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one (ODQ), 7-nitroindazole and D-serine (Sigma Chemical Co, USA), S-nitroso-N-acetyl-penicillamine (SNAP), sildenafil (Pfizer) and MK-801 (Research Biochemicals International, USA) were used. All drugs were dissolved in saline, except ODQ which was dissolved in saline with 1% dimethylsulfoxide (DMSO) and 7-nitroindazole that was dissolved in 5% Tween 80. All drugs were administered by intraperitoneal (i.p.) route in a constant volume of 10 ml/kg body weight, except NMDA, D-serine, ODQ and SNAP which were administered by intracerebroventricular (i.c.v.) route (5 μl/site).
I.c.v. administration was performed under ether anesthesia as previously described (Brocardo et al., 2008) . Briefly, mice were placed inside a glass jar containing ether. The animals remained inside the glass jar for 30 s and immediately after, the i.c.v. administration was performed. Briefly, a 0.4 mm external diameter hypodermic needle attached to a cannula, which was linked to a 25 μl Hamilton syringe, was inserted perpendicularly through the skull and no more than 2 mm into the brain of the mouse. A volume of 5 μl was then administered in the left lateral ventricle. The injection was given over 30 s, and the needle remained in place for another 30 s in order to avoid the reflux of the substances injected. To ascertain that the drugs were administered exactly into the cerebral ventricle, the brains were dissected and examined macroscopically after the test.
Duloxetine was also administered by oral (p.o.) route by gavage in a volume of 10 ml/kg body weight.
In order to investigate the antidepressant-like effect of the duloxetine, it was administered (dose range: 0. In a separate series of experiments, we investigated whether the antidepressant-like effect of duloxetine in the FST is mediated through the blockade of NMDA receptors. To this end, mice were pretreated with NMDA (0.1 pmol/site, i.c.v.) or with D-serine (30 μg/site, i.c.v., a coagonist at the NMDA receptor) and 15 min after, duloxetine (10 mg/kg, p.o.) or vehicle was administered. Sixty minutes later the FST was carried out.
In another set of experiments, we investigated the synergistic effect of a sub-effective dose of duloxetine (0.3 mg/kg, p.o.) with a sub-effective dose of MK-801 (0.001 mg/kg, i.p., a non-competitive NMDA receptor antagonist). Duloxetine or vehicle was administered 30 min before MK-801. A further 30 min was allowed to elapse before the animals were tested in the FST.
To investigate the possible involvement of the L-arginine-nitric oxide pathway in the anti-immobility effects of duloxetine in the FST, in an experimental protocol aimed at increasing NO levels, mice were pre-treated with L-arginine, a precursor of NO (750 mg/kg, i.p., a dose that produces no effect in the FST) or with the NO donor SNAP (25 μg/site, i.c.v., a dose that produces no effect in the FST) or vehicle. Thirty minutes after L-arginine or 15 min after SNAP administration, duloxetine (10 mg/kg, p.o.) or vehicle was injected, and 60 min later the FST was carried out.
In another set of experiments, we investigated the effect of the combined administration of a sub-effective dose of duloxetine (0.3 mg/kg, p.o.) with sub-effective doses of 7-nitroindazole (50 mg/kg, i.p., a specific neuronal NOS inhibitor), ODQ (30 pmol/ site i.c.v., a specific sGC inhibitor) or methylene blue (20 mg/kg, i.p., an inhibitor of both NOS and sGC). Duloxetine or vehicle was administered 30 min before of 7-nitroindazole, methylene blue or 40 min before ODQ. A further 30 min (after i.p. administration of 7-nitroindazole or methylene blue) or 20 min (after i.c.v. ODQ administration) was allowed to elapse before the animals were tested in the FST.
In order to investigate the role of cGMP in the antidepressant action of duloxetine, in an experimental protocol aimed at increasing cGMP levels, mice received an injection of sildenafil (5 mg/kg, i.p., a phosphodiesterase 5 inhibitor) or vehicle 30 min before duloxetine (10 mg/kg, p.o.) and 60 min later the FST was carried out.
The doses of the drugs used were selected on the basis of literature data and on previous results from our laboratory (Almeida et al., 2006; Brocardo et al., 2008; Da Silva et al., 2000; Dhir and Kulkarni, 2007; Kaster et al., 2005a Kaster et al., ,2005b Rosa et al., 2003; Zomkowski et al., 2010) . The doses of duloxetine administered were chosen on the basis of experiments previously performed in our laboratory and literature data (Bomholt et al., 2005; Rénéric and Lucki, 1998) .
In order to evaluate a putative effect of duloxetine on NO levels, an indirect measurement of NO levels via the production of nitrite formed from its metabolism, was performed. Animals received distilled water or duloxetine (10 mg/kg, p.o.). After 60 min, animals were killed by decapitation and hippocampi and cerebral cortices were rapidly removed. Briefly, one cerebral cortex or a pool of three hippocampi were mixed with 25% trichoroacetic and centrifuged at 1800 g for 10 min. The supernatant was immediately neutralized with 2 M potassium bicarbonate. Nitrate (NO3 − ) was reduced to nitrite (NO2 − ) by nitrate reductase. The total NO2 − in the incubation was measured by a colorimetric assay read at 540 nm, based on the Griess reaction. A standard curve was performed using sodium nitrate (0-80 μΜ). Results were expressed as % of control (100%) (Hevel and Marletta, 1994) .
Behavioral tests 2.3.1. Forced swimming test
The FST was conducted using the method of Porsolt et al. (1977) with some modifications. Mice were individually forced to swim in an open cylindrical container (diameter 10 cm, height 25 cm), containing 19 cm of water at 25 ± 1°C; the total duration of immobility during the 6-min test was scored as described previously (Brocardo et al., 2008) . Each mouse was judged to be immobile when it ceased struggling and remained floating motionless in the water, making only those movements necessary to keep its head above water.
Tail suspension test
The total duration of immobility induced by tail suspension was measured according to the method described by Steru et al. (1985) . Briefly, mice both acoustically and visually isolated were suspended 50 cm above the floor by adhesive tape placed approximately 1 cm from the tip of the tail. Immobility time was recorded during a 6 min period (Binfaré et al., 2009 ).
Open-field behavior
The ambulatory behavior was assessed in an open-field test as described previously (Brocardo et al., 2008) . The apparatus consisted of a wooden box measuring 40 × 60 × 50 cm high. The floor of the arena was divided into 12 equal squares. The number of squares crossed with all paws (crossings) was counted in a 6-min session. The light was maintained at minimum to avoid anxiety behavior. The apparatus was cleaned with a solution of 10% ethanol between tests in order to hide animal cues.
Statistical analysis
Comparisons between treatment groups and control were performed by one-way (dose-response experiments) or two-way (experiments dealing with the role of NMDA receptors and L-arginine-NOcGMP pathway in the antidepressant effect of duloxetine) analysis of variance (ANOVA) followed by Tukey's HSD test when appropriate. A value of p b 0.05 was considered to be significant. (Fig. 3D) . A twoway ANOVA did not reveal significant differences for SNAP pre- Corroborating the results presented above which suggest that a putative reduction in NO levels is implicated in the antidepressant-like effect of duloxetine, The results depicted in Fig. 5A show that ODQ (30 pmol/site i.c.v., a specific inhibitor of sGC) in combination with duloxetine (0.3 mg/ 
Discussion
The FST and the TST are quite sensitive and relatively specific for all major classes of antidepressant drugs including tricyclics, serotonin-specific reuptake inhibitors, monoamine oxidase inhibitors, and atypicals (Porsolt et al., 1977; Steru et al., 1985) . Antidepressant drugs are reported to reduce the immobility time of mice in both tests (Porsolt et al., 1977; Steru et al., 1985) . The results presented here show that duloxetine, given systemically (i.p. or p.o. routes), is effective in producing significant antidepressant-like effects, when assessed in the FST, which is the most widely used tool for assessing antidepressant activity preclinically (Cryan et al., 2002) . The antidepressant-like action of duloxetine administered i.p. was confirmed in the TST. This study was performed in female mice, since several studies have shown that the prevalence of depression is about two fold higher in women than in men (Wong and Licinio, 2001) .
The results indicate that anti-immobility effect of duloxetine is not associated with any motor effects, since mice treated with duloxetine did not exhibit increased ambulation when tested in an open-field. This indicates that a psychostimulant effect is not responsible for the decrease in the immobility elicited in the FST. A number of studies have demonstrated that several antidepressants administered by i.p. route produced antidepressant-like effect in the FST in rodents (Ciulla et al., 2007; Dhir and Kulkarni, 2007; Ghasemi et al., 2009; Zomkowski et al., 2010) . Duloxetine was shown to produce antidepressant effect after its administration by the i.p. (40 mg/kg) and subcutaneous routes (10-40 mg/kg) to rats in the FST (Ciulla et al., 2007; Rénéric and Lucki, 1998, respectively) . In the present study, we confirm that duloxetine administered by the i.p. route produces an antidepressant-like effect in the FST in mice, but at a lower doseresponse range (1-30 mg/kg). In order to further reinforce this antidepressant effect, we tested duloxetine in the TST.
Although the FST and TST are widely used for assessing antidepressant activity preclinically, we should take into account that they have some limitations and their validity as simulations of the psychiatric condition is questionable. Some of the limitations are related to the fact that many symptoms of depression are not measurable in preclinical models; they are stressor-based and although there is evidence for a link between depression and stress, this does not always follow. In addition, they respond to the acute antidepressant treatment (Cryan et al., 2002; Cryan and Slattery, 2007) . In spite of these limitations, these tests are useful for studying the mechanisms underlying the antidepressant-like effects of several compounds.
We investigated the participation of NMDA receptors and L-arginine-NO-cGMP pathway in the antidepressant-like effect of duloxetine in the FST. This test was chosen considering that the effects of the modulation of NMDA receptors and NOS-cGMP pathway on the antidepressant-like behavior in this test are well known, as compared to the TST (Almeida et al., 2006; Brocardo et al., 2008; Dhir and Kulkarni, 2007; Ghasemi et al., 2009 Ghasemi et al., , 2010 Harkin et al., 1999 Harkin et al., , 2003 Harkin et al., , 2004 Kaster et al., 2005a Kaster et al., ,2005b Rosa et al., 2003) . For this aim, oral administration of duloxetine was selected because it is the most common route of administration for antidepressants in psychiatric patients. In this study, we showed that the reduction of the immobility time elicited by duloxetine in the FST was prevented by NMDA and D-serine, a coagonist at the NMDA receptor. Similar to our results, the antidepressant-like effect of lithium and escitalopram in the FST was prevented by the pretreatment with NMDA (Ghasemi et al., 2010; Zomkowski et al., 2010) . Moreover, it was shown that NMDA receptor NR2A subunit knockout mice exhibit anxiolytic-like effects in elevated plus-maze, light-dark exploration, novel and familiar open field tests and home cage locomotor activity and antidepressant-like effects in the FST and TST in mice (Boyce-Rustay and Holmes, 2006) . In addition, antidepressants have been reported to reduce binding, expression and function of NMDA receptors (Boyer et al., 1998; Szasz et al., 2007) . An evidence of a direct action of fluoxetine and desipramine inhibiting NMDA-evoked currents in rat cortical cell cultures was reported, suggesting that direct inhibition of NMDA receptors may contribute to the clinical effects of antidepressants (Szasz et al., 2007) . Furthermore, Poleszak et al. (2007) have shown that activation of NMDA receptors by NMDA and D-serine reverses the anti-immobility effect of NMDA receptor antagonists in the FST. The antidepressant effects of fluoxetine, imipramine and reboxetine were also reversed by D-serine (Poleszak et al., 2011) . Therefore, our results are in line with the literature data reinforcing the role of the NMDA receptors in the mechanism of action of antidepressant agents and in the pathophysiology of depression, since they clearly indicate that the antidepressant-like effect of duloxetine is mediated through a blockade of NMDA receptor. However, our behavioral results do not allow us to conclude about the mechanism by which duloxetine interacts with the NMDA receptor and further studies are necessary to better clarify this issue.
The synergistic antidepressant-like effect observed when mice were treated with the non-competitive NMDA receptor antagonist MK-801 combined with duloxetine reinforces the assumption that duloxetine exerts its antidepressant-like effect by blocking NMDA receptor activation. It is known that MK-801 preferentially binds to the activated NMDA receptor complex (Javitt and Zukin, 1989) interacting with a site located within the NMDA channel pore. In concordance with our results, a study recently demonstrated that the combined treatment of sub-effective doses of paroxetine and MK-801 exerted antidepressant-like effect in the FST in mice (Ghasemi et al., 2009) . Moreover, some studies have demonstrated a synergistic effect of NMDA receptor antagonists with antidepressants and lithium in the FST (Ghasemi et al., 2010; Rogóz et al., 2002) . However, there are little data on the mechanisms by which NMDA antagonists enhance the effects of antidepressants in the FST. A microdialysis study has demonstrated that acute administration of noneffective doses of the NMDA antagonist amantadine combined with noneffective doses of several antidepressants (paroxetine, reboxetine, budipine and clomipramine) increases the cortical release of 5-HT in freely moving rats (Owen and Whitton, 2005) . Hence, we cannot rule out the possibility that the antidepressant-like effects elicited by treatment of mice with sub-effective doses of duloxetine and NMDA antagonists may be due to their effects on the central 5-HT release.
The L-arginine-NO-cGMP pathway has been implicated in the pathogenesis of depression (Kaster et al., 2005a (Kaster et al., , 2005b Mantovani et al., 2003) . NO plays a significant role in the central nervous system and pharmacological manipulation of the NO pathway may constitute a novel therapeutic approach for the treatment of depression (Harkin et al., 2003 (Harkin et al., , 2004 . In this study, we showed that the reduction of immobility time elicited by duloxetine in the FST was reversed by pre-treatment of mice with L-arginine (NOS substrate) or SNAP, an NO donor. Similarly to our results, the antidepressant-like effects of imipramine, escitalopram, paroxetine and venlafaxine were also blocked by pre-treatment with L-arginine (Dhir and Kulkarni, 2007; Ghasemi et al., 2009; Harkin et al., 2004; Zomkowski et al., 2010) . In previous studies, our group demonstrated that L-arginine and SNAP reversed the antidepressant-like effects of putative antidepressant agents such as zinc chloride (Rosa et al., 2003) , adenosine (Kaster et al., 2005b) , memantine (Almeida et al., 2006) , folic acid (Brocardo et al., 2008) and ascorbic acid (Moretti et al., 2011) . Therefore, a great amount of literature data points to a significant role of nitrergic system in the mechanism of action of antidepressant agents. Corroborating this notion, our results indicate that the effect of duloxetine may be dependent on the inhibition of NO synthesis. Further reinforcing this assumption, in this study, the pre-treatment of mice with a sub-effective dose of 7-nitroindazole (a specific neuronal NOS inhibitor), methylene blue (direct inhibitor of both NOS and sGC) or ODQ (a specific inhibitor of sGC) produced a synergistic antidepressant-like effect with duloxetine. Corroborating these results, duloxetine treatment was able to decrease NOx levels in the hippocampus and cerebral cortex. Together this set of results suggests that the inhibition of NO synthesis is implicated in the antiimmobility effect of duloxetine in the FST and is in accordance with the fact that NOS inhibitors exert antidepressant-like effect in animal models of depression (Eroglu and Caglayan, 1997; Volke et al., 2003; Yildiz et al., 2000) . In addition, in line with our results, studies have demonstrated that 7-nitroindazole potentiated the antidepressantlike effect of venlafaxine (Dhir and Kulkarni, 2007) , imipramine and fluoxetine (Harkin et al., 2004) in the FST. Similarly to our results, a study showed that methylene blue potentiated the antidepressantlike effect of venlafaxine in the FST (Dhir and Kulkarni, 2007) . Moreover, it has been reported that the antidepressant-like effect produced by ODQ in the FST in rats was reversed by pre-treatment with L-arginine (Heiberg et al., 2002) . In line with our results, ODQ potentiated the antidepressant-like effects of lithium (Ghasemi et al., 2008) , adenosine (Kaster et al., 2005b) and memantine in the mouse FST (Almeida et al., 2006) . These results reinforce our hypothesis that the anti-immobility effect of duloxetine in the FST is dependent on the decrease in NO synthesis and also that it may be mediated through the reduction of cGMP, likely as a consequence of the reduction of NO synthesis. Noteworthy, a study reported that L-arginine was able to partially prevent the inhibition of genital vascular responses induced by duloxetine in rabbits, reinforcing the notion that this antidepressant may act on NOS system (Angulo et al., 2004) . Although the present study does not allow us to know exactly the mechanism responsible for the observed behavioral effects, one possibility is that the effects are indirectly dependent on an increase in the release of 5-HT. It is interesting to note that the effects of NOS inhibitors in the FST are reported to be dependent on endogenous 5-HT, since the depletion of 5-HT caused by the treatment of rats with PCPA prevented the effects of NOS inhibitors in the FST (Harkin et al., 2003) . Furthermore, some studies have demonstrated that inhibition of NOS can modulate the release of central 5-HT (Kiss, 2000; Smith and Whitton, 2000; Wegener et al., 2000) .
Of note, we also showed that the pre-treatment of mice with sildenafil (selective type 5 phosphodiesterase inhibitor) prevented the antidepressant-like effect of duloxetine in the FST. Sildenafil increases the cGMP level in target tissues (Beavo, 1995) and was previously reported to reverse the anti-immobility effect of ODQ in the mouse FST (Kaster et al., 2005b) . Our results are somewhat in accordance with the literature data that showed that the reduction in the immobility time elicited by the antidepressants venlafaxine (Dhir and Kulkarni, 2007) and escitalopram (Zomkowski et al., 2010) was also prevented by the pre-treatment with sildenafil. This finding reported here reinforces the notion that duloxetine exerts its effect in the FST by decreasing cGMP levels.
In conclusion, our study demonstrated that duloxetine exerts an antidepressant-like effect in the FST in mice when administered intraperitoneally and orally, confirming the results obtained previously (Ciulla et al., 2007; Rénéric and Lucki, 1998) in the FST in rats. In addition, its antidepressant-like effect also was shown in the TST in mouse. Moreover, our results significantly extend literature data by indicating for the first time the involvement of the NMDA receptors and L-arginine-NO-cGMP pathway in the antidepressant-like action of duloxetine in the FST. The acute duloxetine treatment also decreased hippocampal and cerebrocortical NOx levels. It supports the notion that the blockade of NMDA receptor, with the consequent inhibition of NO and cGMP production may be critical to the antidepressant action of duloxetine and further reinforces the role of NMDA receptors and L-arginine-NO-cGMP pathway, besides the monoaminergic systems, in the mechanism of action of current prescribed antidepressant agents.
